Trial Profile
Rapamycin [sirolimus] for Prevention of Chronic Graft-Versus-Host Disease
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2017
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 15 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Mar 2008 New trial record.